The Overview
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management products for the treatment of acute and chronic pain. We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients’ lives.
We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Our lead product candidate, SP-102 (“SEMDEXATM”) (10 mg, dexamethasone sodium phosphate viscous gel), if approved, has the potential to become the first FDA-approved non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe chronic radicular pain/sciatica, containing no preservatives, surfactants, solvents, or particulates and will be available in a pre-filled syringe formulation.
We are developing SP-102 (SEMDEXA™) to be an injectable viscous gel formulation of a widely used corticosteroid designed to address the serious risks posed by off-label epidural steroid injections (“ESI”), which are administered over 12 million times annually in the United States.
Our Vision
Our vision is to become the leading pain management company delivering novel non-opioid and non-addictive treatments to provide safe, effective and durable relief of multiple pain conditions. To accomplish this, the principal elements of our strategy are the following:
- Develop and commercialize SEMDEXA as a novel epidural injection for the first approved treatment of sciatica.
- Expand our product portfolio by developing or acquiring non-opioid assets that leverage our existing infrastructure.
- Maximize the commercial value of our product candidate
- Investing in early and late-stage research programs to expand our pipeline and capabilities through selectively acquiring highly differentiated technologies
- Semnur Pharmaceuticals is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life.
- Semnur Pharmaceuticals is wholly-owned subsidiary of Scilex Holding Company.
- Information within the Investors section of the website is intended for an investment audience only.
